General Information of Drug (ID: DMMF5IE)

Drug Name
GS-9883 Drug Info
Synonyms
Bictegravir; Bictegravir (USAN/INN); Bictegravir [INN]; Bictegravir [USAN:INN]; SB18851; SOLUWJRYJLAZCX-LYOVBCGYSA-N; (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide; 1611493-60-7; 8GB79LOJ07; BCP25703; BDBM330048; CHEMBL3989866; DB11799; GS 9883; GS-9883; GS-9883-01; SCHEMBL15914278; UNII-8GB79LOJ07
Cross-matching ID
PubChem CID
90311989
CAS Number
CAS 1611493-60-7
TTD Drug ID
DMMF5IE
INTEDE Drug ID
DR0212

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DME
Drug Status:
Approved Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [2]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [3]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [4]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [5]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [6]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [7]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [8]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [9]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [3]
Verapamil DMA7PEW Angina pectoris BA40 Approved [10]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [11]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [12]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [13]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [14]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [15]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [16]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [17]
Metronidazole DMTIVEN Abscess Approved [18]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [19]
Ethanol DMDRQZU Chronic pain MG30 Approved [20]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [1]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [1]

References

1 Bictegravir, a novel integrase inhibitor for the treatment of HIV infection. Drugs Today (Barc). 2019 Nov;55(11):669-682.
2 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
3 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
4 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
5 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
6 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
7 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
8 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
9 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
10 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
11 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
12 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
13 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
14 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
15 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
16 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
17 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
18 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
19 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
20 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.